Roche Looks to FCB for $30 Mil. Account

Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.

NEW YORK Interpublic Group’s Foote Cone & Belding is poised to assume direct-to-consumer advertising chores from pharmaceutical company Hoffman-La Roche for two drugs to treat hepatitis C, sources said. Annual media spending for upcoming campaigns could exceed $30 million, sources said.

FCB in New York competed in a review that included three other undisclosed agencies. Final pitches were held last week, sources said. No consultant was used.

The drugs, Pegasys and Copegus, received Food and Drug Administration approval two years ago, but FCB would create the first DTC campaign for them, sources said.



AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in